The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA
Hagop M. Kantarjian, Shilpa Paul, Jigar Thakkar, Elias Jabbour
Topics & Concepts
MedicinePonatinibImatinibChronic myeloid leukaemiaDasatinibMyeloid leukemiaImatinib mesylateOncologyTyrosine-kinase inhibitorPharmacologyInternal medicineCancerChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research